Articles On Paradigm Biopharmaceuticals (ASX:PAR)

Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares could have huge upside potential. That's the view of analysts at Bell Potter, which believe the ASX biotech stock could be a great option for investors with a high tolerance for risk. What i...

S&P/ASX 200 Health Care (ASX: XHJ) shares are up 0.44% on Tuesday while the ASX 200 is up 0.23%. But these three ASX healthcare shares are knocking it out of the park on this otherwise lacklustre day. Here's why. Paradigm Bio...

The S&P/ASX 200 Index (ASX: XJO) is having another day to forget on Friday. In afternoon trade, the benchmark index is down 1.45% to 7,532.3 points. Four ASX shares that are not letting that hold them back today and are avoiding the ma...

Paradigm submits key documents to US FDA to advance its pivotal Phase 3 trial of iPPS/Zilosul Biotech also submits a draft of protocol for the Phase 3 pivotal clinical trial to FDA for review and comment Pending FDA clearance, PAR aims to...

Paradigm Biopharma submits response to the FDA INOVIQ says its blood test on cancer is highly accurate   Paradigm sends response to the US FDA Paradigm Biopharmaceuticals (ASX:PAR) announced that it has submitted important documents to t...

Paradigm Biopharma (ASX:PAR) has announced its completion of a submission to the US FDA to progress to Phase III of its osteoarthritis treatment ‘program.’ Within the application Paradigm bundled the results of five nonclinical studies a...

  ASX to fall on Friday on the back of strong US jobs report Netflix down 5pc after reporting Q1 results Bitcoin halving to happen today or tomorrow   Aussie shares are set to fall on Friday after the US released another strong jobs repo...

Several ASX companies are repurposing or resurrecting abandoned or under utilised drugs  Paradigm Biopharmaceuticals identified the potential of FDA-approved PPS that has a long track record of treating inflammation Starpharma has develope...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Every country worldwide is seeing growth in both size and percentage of older people in their population Lodge Partners says anti-aging and longevity has become a focus area for pharmaceutical and biotech companies LTR Pharma is helping ol...

Paradigm Biopharma’s Phase 2 meets primary endpoint TrivarX collaborates with US university to advance sleep research   Paradigm’s successful Phase 2 trial Paradigm Biopharma (ASX:PAR) announced that its Phase 2 clinical trial, PARA_MPSVI...

Research reports on ASX-listed companies, to download in full. **** -Actinogen Medical ((ACW)) by Research as a Service (RaaS): https://www.fnarena.com/index.php/download-article/?n=2B537F21-A3D7-CB04-98294578CBAE8E12 -Amaero International ...

Tim Boreham highlights the success of Paradigm Biopharmaceuticals' joint pain drug ahead of a capital raising. by Tim Boreham ASX code: ((PAR)) Share price: 41.5c Shares on issue: 281,756,625 (pre capital raise) Market cap: $116.9 m Executi...

Despite improving sentiment in the life sciences sector, investors are savagely discounting pre-clinical drug developers with a long path to approval. That’s fair enough – investors are risk averse generally – but many worthy drug developer...

The ASX200 started November with a gain of more than three-quarters of a per cent (.85 of a per cent). Most sectors were in the green. Real estate and health care both had strong runs. In the green BHP Group (ASX:BHP) was up 1.5 pe...

The S&P/ASX 200 Index (ASX: XJO) is having a strong session on Wednesday. In afternoon trade, the benchmark index is up 0.65% to 6,825.3 points. Four ASX shares that have failed to follow the market's lead today are listed below. Here...

IDT provides strong quarterly update Paradigm tumbles 30pc after emerging from trading halt   IDT’s growth driven by all business segments Victoria-based pharmaceutical manufacturing company, IDT Australia (ASX:IDT), provided an update on...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has returned from its trading halt and crashed deep into the red. In morning trade, the ASX All Ords share is down 34% to a 52-week low of 40.5 cents. Why is this ASX All Ords shar...

Benchmark ASX closes below 6,800 points  All Sectors in red, but for IT Small caps led, in a very big way, by TG6    The benchmark has ended sharply lower after weak overseas leads, strong retail data and an all-round international-flavou...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Research reports on ASX-listed companies, to download in full. **** -Amaero International ((3DA)) by Research as a Service (RaaS): https://www.fnarena.com/index.php/download-article/?n=BF0A410A-F5BF-4E00-5CA139523262B26D –Bell Financial Gro...

The Australian sharemarket increased in value on Wednesday, as China's gross domestic product (GDP) for July-September grew by 4.9% compared to the previous year.  At the closing bell, the S&P/ASX 200 was 0.3 per cent higher at 7,077.60...

There have been some big movers in the healthcare sector on Wednesday. Here's why these ASX healthcare shares are up over 10% today: Mayne Pharma Group Ltd (ASX: MYX) The Mayne Pharma share price is up over 13% to $3.12. Investors have be...

  Don't miss Friday's webinar discussing imaging tech, laser tech and agricultural REITs. Click here to register. Whitehaven Coal (ASX:WHC) has been placed in a trading halt following an announcement by BHP that Whitehaven Coal is the prefe...

18 Oct 2023 - A snapshot of the stocks on the move, featuring Whitehaven Coal (ASX:WHC), Paradigm Biopharmaceuticals (ASX:PAR), Noxopharm (ASX:NOX) and Liontown Resources (ASX:LTR)…

Paradigm Biopharma (ASX:PAR) reports it has proven it can reverse the degradation of cartilage in patients with osteoarthritis The company is using injectable pentosan polysulfate sodium (iPPS) delivered twice weekly over six weeks...

ASX futures were down 0.43 per cent at 8.30 am AEDT as US indexes landed in the red on Friday. The S&P 500 ended down by half a per cent and the NASDAQ down 1.23 per cent. The Dow Jones ended up 0.12 per cent. In the US, energy w...

  Paul Rennie – Founder and Managing Director – Paradigm Biopharmaceuticals Limited (ASX:PAR) is a global biopharmaceutical company. Its current focus is a drug for the treatment of osteoarthritis.

The S&P/ASX 200 surged back above 7000 on Tuesday, driven by a shift in rhetoric from US Federal Reserve members towards a more dovish stance and signs of easing inflation. The benchmark closed 1% higher at 7040, marking its best one-da...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

  Paradigm Pharmaceuticals phase II study for treatment of knee osteoarthritis reports successful outcome at day 356 Clinical outcomes improvement observed for iPPS twice weekly compared to placebo control Company now intends to proceed wi...

Paradigm Biopharma set to submit application to TGA EMVision uses artificial intelligence simulation   Paradigm to submit TGA application after successful trial Paradigm Biopharmaceuticals (ASX:PAR) jumped 13% this morning after reporting...

Paradigm Biopharma (ASX:PAR) reports injectable pentosan polysulfate has led to a decrease in self-reported pain in osteoarthritis (OA) patients The company says results show iPPS is likely a superior drug compared to other major treatm...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has been catching the eye on Tuesday. At one stage today, the ASX healthcare share was up over 18% to 73.5 cents. The Paradigm share price has pulled back a touch since then but re...

Oil prices held steady following a significant surge as Israel indicated that its retaliation against Hamas attacks had just begun, raising concerns of increased instability in the region. The conflict's potential impact on global oil suppl...

Late-stage drug development company Paradigm Biopharmaceuticals (ASX: PAR) has announced positive study data from a Phase 2 clinical trial of injectable pentosan polysulfate sodium (iPPS) for the treatment of acute pain associated with knee...

10 Oct 2023 - A snapshot of the stocks on the move, featuring Atlantic Lithium (ASX:A11), Raiden Resources (ASX:RDN) and Paradigm Biopharmaceuticals (ASX:PAR).

  Atlantic Lithium (AIM:ALL, ASX:A11, OTCQX:ALLIF) receives authorisation to commence the diversion of the transmission lines crossing the Mankessim Licence, moving a step closer to shovel readiness at the Ewoyaa Lithium Project. Shares are...

Stockhead’s Top 10 at shortly-before-11-ish, produced with gritted teeth as, once again, the local council has decided that it needs to pay some drongo to stand outside my house all day waving a leaf blower around while screaming into his c...

Research reports on ASX-listed companies, to download in full. **** –Amaero International ((3DA)) by Research as a Service (RaaS): https://www.fnarena.com/index.php/download-article/?n=740BB0E6-015D-39AE-7477F8A8DFBEC04C –Millennium Service...

Research reports on ASX-listed companies, to download in full. **** –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=628D02C0-B9D8-EA23-2DB35CB4E58A7CBE –AFT Pharmaceuticals ((AFT)) by Edi...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small decline. The benchmark index is currently down 0.15% to 7,235.2 points. Four ASX shares that are falling more than most today are listed below. Hereâ€...

Futures suggest Australian shares will open relatively unchanged in the face of the RBA interest rate decision this afternoon. Here are some ASX-listed companies with news out today: In healthcare, Paradigm Biopharmaceuticals (PAR) h...

Research reports on ASX-listed companies, to download in full. **** –AFT Pharmaceuticals ((AFP)) – Edison Research: https://www.fnarena.com/index.php/download-article/?n=5CCC26AF-A670-63C8-370E356F819BE3C4 –Barrow Handley Global Share Fund...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Paradigm Bio says drug is effective in osteoarthritic dogs HeraMED signed a deal with Fond, a US-based global SaaS platform The first patient has been dosed in Imugene’s clinical trial   Late stage biotech Paradigm Biopharmaceuticals (ASX...

The ASX is set to open lower on Thursday US debt ceiling deal passed to Senate after the House voted 241-187 Crude prices have fallen by another -2.7%   Aussie shares are set to open lower on Thursday after the shock inflation report yest...

Paradigm Biopharma launches clinical trial website to support development program for knee osteoarthritis therapy. MELBOURNE, Australia, May 25, 2023 /PRNewswire/ — With the launch of a new website dedicated to their global clinical trials...

Research reports on ASX-listed companies, to download in full. –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=F863639F-EF2C-E5CB-37099553DD439B58 –AFT Pharmaceuticals ((AFP)) by Edison R...